• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: PULMONX CORPORATION ZEPHYR ENDOBRONCHIAL VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

PULMONX CORPORATION ZEPHYR ENDOBRONCHIAL VALVE Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Cardiac Arrest (1762); Pneumothorax (2012)
Event Date 06/01/2023
Event Type  Injury  
Manufacturer Narrative
Pneumothorax is the most common side effect associated with the zephyr valve treatment (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).Targeted lobar deflation likely causes inflation of the ipsilateral lobe, which can result in a tear of the already compromised parenchymal tissue of the emphysematous ipsilateral lobe, resulting in a pneumothorax (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).In the liberate study (ide clinical study used to support pma p180002's approval), 26.6% of the zephyr valve subjects experienced a pneumothorax in the treatment period ([less than or equal to 45 days).These were managed using standard of care procedures as per previously published guidelines (valipour, arschang, et al.Respiration 87.6 (2014): 513-521).In 17.4% of the events, the pneumothorax resolved without any additional intervention with subjects under careful observation.In over half the events (56.5%), the pneumothorax was managed with a chest-tube only.An additional 13% of the events were managed with a chest-tube and the temporary removal of one or more valves, while another 13% of the events were managed with a chest-tube and removal of all the implanted valves.Upon successful resolution of the pneumothorax, removed valves can be replaced.Patients that experienced a pneumothorax experienced clinical benefits of the zephyr valve treatment that were similar to the benefits experienced by patients who did not have a pneumothorax.The zephyr ebv system ifu and pulmonx training program both specifically reference pneumothorax as a known side effect of this procedure and the published guidelines (valipour, arschang, et al."expert statement: pneumothorax associated with endoscopic valve therapy for emphysema-potential mechanisms, treatment algorithm, and case examples." respiration 87.6 (2014): 513-521).The reported event aligns with the experience observed in the liberate clinical study and is an expected side effect to the zephyr valve treatment.
 
Event Description
The patient had a bronchoscopic lung volume reduction procedure with four zephyr valves placed in the right upper lobe and right middle lobe on (b)(6) 2023.The patient was discharged home on (b)(6) 2023.On (b)(6) 2023, while at home the patient felt a "pop", was acutely short of breath and called 911.The emergency medical responders found her pulseless and unresponsive and provided two rounds of medications and cpr.The patient had return of spontaneous circulation.The patient had experienced a tension pneumothorax and a 28 fr chest tube was placed.The patient was transferred to the treating hospital, was extubated on (b)(6) 2023 and was neurologically intact.The patient suffered sternal and rib fractures from cpr.The patient had daily chest x-rays and a chest ct scan on (b)(6) 2023.After resolution, the chest tube was removed on (b)(6) 2023 and the patient was discharged from the hospital.The treating physician believes the cardiac arrest was secondary to the tension pneumothorax.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ZEPHYR ENDOBRONCHIAL VALVE
Type of Device
ENDOBRONCHIAL VALVE
Manufacturer (Section D)
PULMONX CORPORATION
700 chesapeake drive
redwood city 94063
Manufacturer Contact
mahtab fatemi
700 chesapeake drive
redwood city, CA 94063
6504072823
MDR Report Key17226407
MDR Text Key318176531
Report Number3007797756-2023-00207
Device Sequence Number1
Product Code NJK
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P180002
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,User Facility,Company Representative
Reporter Occupation Non-Healthcare Professional
Remedial Action Patient Monitoring
Type of Report Initial
Report Date 06/27/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/29/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Date Manufacturer Received06/05/2023
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age65 YR
Patient SexFemale
Patient Weight65 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-